Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 187 results
Filters: Author is Ribaudo, Heather  [Clear All Filters]
Found 187 results.

Adult

Haubrich RH, Riddler SA, Ribaudo H, et al. "Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection." AIDS. 2011;25(18):2269-78.
Cohen MS, Chen YQ, McCauley M, et al. "Prevention of HIV-1 infection with early antiretroviral therapy." N. Engl. J. Med.. 2011;365(6):493-505.
Wilkin TJ, Lalama CM, McKinnon J, et al. "A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256." J. Infect. Dis.. 2012;206(4):534-42.
Taiwo BO, Chan ES, Fichtenbaum CJ, et al. "Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study." Clin. Infect. Dis.. 2015;61(7):1179-88.
Taiwo B, Gallien S, Aga E, et al. "Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy." J. Infect. Dis.. 2011;204(4):515-20.
Hammer SM, Ribaudo H, Bassett R, et al. "A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen." HIV Clin Trials. 2010;11(6):312-24.
Wallis CL, Aga E, Ribaudo H, et al. "Drug susceptibility and resistance mutations after first-line failure in resource limited settings." Clin. Infect. Dis.. 2014;59(5):706-15.
Clifford DB, Evans S, Yang Y, Acosta EP, Ribaudo H, Gulick RM. "Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)." HIV Clin Trials. 2009;10(6):343-55.
Gripshover BM, Ribaudo H, Santana J, et al. "Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118)." Antivir. Ther. (Lond.). 2006;11(5):619-23.

Anti-Retroviral Agents

Cohen MS, Chen YQ, McCauley M, et al. "Prevention of HIV-1 infection with early antiretroviral therapy." N. Engl. J. Med.. 2011;365(6):493-505.

Pages